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Introduction 
 
Healthcare-related research is, understandably, dominated by medical science.  
Research ethics bodies ensure that such research is conducted according to rigorous 
scientific standards whilst protecting the rights and interests of patients.  More 
recently, ethical governance has been extended to social science research in health 
and other areas – but this has occurred in an uneven way.  The various social science 
associations have yet to agree on a set of universal rules (Hoeyer et al, 2005).     
 
When it comes to health-care related research, medical researchers are typically in 
more powerful positions than social scientists. Power is exercised at the level of ethics 
committee approval (which in the health arena is dominated by medical researchers) 
and at the level of healthcare facilities that are, necessarily, controlled by medical 
personnel (where some of whom may also be researchers).  While there is an 
emerging body of literature commenting on the dominance of medical scientists in 
research ethics bodies (see e.g. Phal, 2005; Bosk, 2005 and Alderson, 2005), the 
exercise of power at the level of the health facility has yet to be properly considered.  
This paper begins to explore this topic by means of two South African case studies of 
the largely unaccountable exercise of power by medical practitioner/researchers over 
social scientists with regard to providing access to research subjects.  In so doing, it 
raises questions about how we think about the informed consent.   
 
The first code of ethics for medical research was the Nuremburg code (1947) in which 
informed consent was codified on the principle that individuals must never be 
sacrificed for the benefit of society (Hoeyer, et al, 2005). This overturned the hitherto 
existing paternalist and complacent ‘Hippocratic’ approach which assumed that 
medical researchers and doctors were the only agents capable of making appropriate 
judgments about medical research (Alderson, 2005).  This was followed by the 1964 
Declaration of Helsinki (subsequently revised five times by the World Medical 
Association (WMA)) that established a set of fundamental principles for medical 
research.  This has been supplemented by a set of additional ethical guidelines for 
healthcare-related research, each emanating from specific regulatory bodies.  These 
include: the Council for International Organizations of Medical Sciences (CIOMS, 
2002); Council of Europe (COE, 2004); European Union (EU, 2001); European 
Group on Ethics in Science and New Technologies (EGE, 2003); Medical Research 
Council (MRC, 2004); and Nuffield Council on Bioethics (UK) (NCOB, 2002).  The 
main purpose of all these codes of conduct is to protect the subjects of medical 
research by requiring their informed consent, protecting confidentiality and ensuring 
that the real and potential benefits of participation can reasonably be expected to 
outweigh the costs.  Since then, independent review boards (IRBs) in the United 
States, and Research Ethics Committees (RECs) in the United Kingdom and 
elsewhere have applied these basic principles to medical research.   
 
These principles and practices have now been extended to cover social science 
research.  While this is necessary to protect the interests of research subjects, in 
practice this has tended to result in the prioritization of medical research over that of 
social science research.  Limited representation of social scientists on research ethics 
bodies results in a typically poor appreciation of social science research techniques – 
especially with regard to qualitative and ethnographic approaches (Bosk, 2005; 
Alderson, 2005).  This can result in a game of ‘my discipline is more rigorous than 
your discipline’ played by medical researchers in IRBs against social scientists (Pahl, 
2005).  This game is loaded further in favour of medical researchers by the 
application of the medical risk-benefit paradigm to social science research.  Whereas 
the standard piece of medical research involves a randomized control trial in which 
research subjects are also patients who stand to benefit directly from the development 
of new drugs (whilst also facing real risks from unanticipated side effects) – social 
science techniques are more varied and are, by their very nature, unable to result in 
the immediate and direct personal benefits to the research subjects of the kind that 
successful drug therapies could bring.  By its very nature, the ‘benefits’ of social 
science research are reaped at the level of society rather than the individual.  At the 
very least, it leads to intangible benefits by adding to the body of social science 
knowledge – and at best it leads to more tangible benefits through informing the 
development of new and better policy interventions, but even where this happens, the 
‘benefits’ are likely to accrue to individuals in the future, rather than to the research 
subjects themselves.  A narrow application of the requirement that the research 
‘benefits’ the research subject is thus necessarily always going to be biased against 
the social scientist.  
 
In addition, there are clear difficulties involved in understanding potential ‘risks’.  In 
medical trials, the risks are typically and easily understood as ‘side-effects’ of the new 
drugs.  In social science research, the risks are more difficult to isolate and evaluate.  
This can result in ad hoc and inappropriate (even absurd) judgments.  For example, an 
IRB in the United States refused a social scientist permission to ask his class of 
university students to participate in and write about their experience of a recreational 
group activity over the weekend on the grounds that the project might expose student 
to unanticipated harm by encouraging them to go out on a Saturday night (Bosk, 
2005).  A similarly risk-averse approach is often evident with regard to evaluation of 
potential ‘risk’ to research subjects of being asked potentially upsetting or sensitive 
questions (Pahl, 2005).  Rather than leave it up to the researcher to decide whether a 
particular research subject should be exposed to a continued line of sensitive question, 
research ethics bodies are prone to removing such questions – often with no or little 
appreciation of the fact that research subjects often want to discuss such topics as they 
are of particular interest to them.  Pahl thus complains that ethics committees can be 
seen as standing in the way of patients deciding for themselves whether they want to 
participate in the research process themselves (ibid).  
 
In other words, there seems to be a danger that the old problem with the Hippocratic 
approach (in which doctors made the decision about what was or was not in the 
interests of the patient) has re-emerged within the context of medically-dominated 
research ethics bodies deciding what social science is or is not in the interests of 
research subjects. Rather than ensure that research subjects understand the potential 
risks and benefits of participating in a social science research project – i.e. are in a 
position to give informed consent – the very choice may be removed from them at the 
outset by a research ethics evaluation process based on a (possibly loaded and biased) 
understanding of potential risks and benefits.  
 
This removal from research subjects of the right to make an informed choice as to 
whether they want to participate in social science research can occur both at the level 
of the research ethics body (i.e. at the point when the social scientist seeks ethics 
approval for the research) and at the level of the clinic or health facility when the 
social scientist seeks permission to interview people making use of the facility.  
Whereas the former problem can (at least in principle) be addressed by increasing the 
representation of social scientists on research ethics bodies, there are no effective 
mechanisms in existence to address the exercise of power by medical practitioners 
who effectively control access to patients by virtue of the fact that they provide 
medical services to them.   This problem is even more acute when the medical 
practitioners are themselves also researchers – and hence may have research-related, 
self-interested, reasons to deny access to social science researchers.  
 
Some attention has been paid to the problem of ‘dual loyalty’ – i.e. when a clinician 
experiences a role conflict between their professional duties to a patient, and the 
obligations, expressed or implied, real or perceived, to the interests of a third party 
(see Physicians for Human Rights and University of Cape Town Health Sciences 
Faculty, 2003).  However, as Singh points out, this problem has yet to be applied to 
dual loyalty in medical research – especially when the roles of clinician and 
researcher merge: “In the practice-research context this translates to the physician-
researcher’s primary interest (duty of care towards the patient-subject) being 
undermined by secondary factors (such as loyalty to the study/sponsor)” (2005: 395).  
He cites the example of a 1997 study on the relationship between viral load and HIV-
transmission amongst sero-discordant couples as manifesting this problem:  should 
the researcher/clinicians in their role as doctor have been more forthright about the 
risks of transmission to the sero-negative partner; or should they have withheld the 
information in the interests of the scientific study?  The emerging ‘answer’ to this 
problem seems to be for clinician/researchers to explain to their patients about their 
dual roles, and for it to be made clear to patients that they can withdraw from the 
study without loss of medical help (see discussion in Singh, 2005: 396-399).   
 
Unfortunately, no attention has yet been paid to the ethical problem of clinicians 
denying social scientists access to ‘their’ patients not because they are worried about 
the adverse implications of the social science research for the patients, but because 
they do not want any other research (besides their own) being conducted on the 
patients.    
 
This paper explores some of the ethical issues arising from the exercise of self-
interested, research-related, power by medical researcher/practitioners over social 
scientists.  I present two case studies, both arising out of my experience working as a 
social scientist with, and alongside medical researcher/practitioners in South Africa.  
It is thus necessarily subjective and impressionistic – but nevertheless provides 
concrete examples of the kinds of problems that can arise when medical 
researcher/practitioners and social scientists collide ‘in the field’.   
 
Each case study throws up different ethical issues for consideration.  However, a 
common thread running through both of them is my observation that doctors/medical 
researchers use their power over social scientists not only to protect their own 
research turf, but because they see themselves as being in a morally and intellectually 
superior position.  They believe that they are in a morally superior position because 
‘only they really help’ people by dispensing medicine (whereas social scientists can, 
at best, do little more than contribute in some amorphous way to the policy 
environment) – and they believe that they are in an intellectually superior position 
because their research is based on ‘hard’ science (rather than ‘soft’ social science).  
Whilst acknowledging the power of medical science, social scientists would 
nevertheless insist that their research methodologies are appropriate for a different – 
but equally important – set of questions. Denying social scientists access to patients 
thus effectively limits to research field to a very narrow set of issues.     
 
Medical researcher/practitioners are in a powerful position to dictate the research 
agenda largely because they have access to extraordinarily large budgets to treat and 
research their patients.  In a very real sense, these medical practitioner/researchers do 
indeed control ‘their’ patients/research subjects – and in the Case 2 below, they do not 
hesitate to use this power and deny others research access to them.  The temptation to 
regard social scientists as irrelevant at best (and distracting at worst) poses serious 
problems for research collaboration between medical and social scientists.  Not only 
is there the danger that social science research will be side-lined – but that medical 
researchers will be in a position to dictate what gets studied, and perhaps also be in a 
position to appropriate and twist social science results to suit their larger interests (as 
occurred in Case 1).  In other words, there are issues of research ethics and good 
science at stake. 
 
The South African case studies presented here illustrate these problems in particularly 
stark ways largely because of the context of AIDS crisis.  With just under a fifth of 
the adult population HIV-positive, and given the government’s reluctance to roll-out 
antiretroviral therapy with any sense of urgency, there is substantial pressure (both in 
terms of resources and emotional energies) on healthcare practitioners.  Their 
irritation with social science research is thus in some way understandable.  However, 
as the AIDS crisis is both a social and health crisis, and given that social scientists are 
better placed than medical practitioners to understand the social and behavioural 
context governing individual adherence to antiretroviral therapy, the effective control 
of medical researcher/practitioners over access to research subjects is highly 
problematic.    
 
The first part of the paper sketches the context of AIDS in South Africa and the 
particular research challenges posed by the nascent antiretroviral treatment rollout.  
This is then followed by a discussion of two cases of uncontrolled ‘gate-keeping’ by 
self-interested medical practitioners/researchers in Cape Town.  The first illustrates 
the problem of placing narrowly defined institutional interests over that of a broader 
social interest.  The second illustrates the problem of self-interested gate-keeping by 
medical researchers who place bio-medical concerns over social-psychological 
considerations.  
 
 
The Context: AIDS in South Africa and the Challenge of Providing Highly 
Active Antiretroviral Therapy 
  
AIDS is a very serious problem in South Africa. Over a quarter of pregnant women 
who attend antenatal government clinics are HIV-positive. Using this and other 
demographic data such as deaths by age, gender and race, South Africa’s premier 
demographic model (ASSA2002) estimates that 18.7% of adults between the ages of 
20-64, and 10.8% of all South Africans, were HIV-positive in 2004. These estimates 
are consistent with the results of a national survey of HIV prevalence conducted in 
2001 (Shisana and Simbayi, 2002). Figure 1 plots trends in the raw HIV prevalence 
data from the government antenatal survey as well as key outputs from the 
ASSA2002 model.   
 
The AIDS pandemic amounts to a socio-economic crisis of significant proportions. 
AIDS undermines the economic security of households by reducing the productivity 
of (and eventually killing) mainly prime-age adults whilst simultaneously diverting 
scarce household resources towards medical expenditure. This has been especially 
problematic for poor African households in South Africa (see evidence cited in 
Nattrass, 2004).  Under these circumstances, the provision of highly active 
antiretroviral therapy (HAART) has the potential to impact positively on the lives of 
AIDS patients and on society as a whole.   
 
According to the ASSA2002 model, about 500,000 people are in Stage 4 of AIDS and 
thus in need of HAART.  Yet as of April 2005, fewer than 30,000 people were on 
HAART in South Africa – this despite the fact that the government promised as early 
as October 2003 to have provided HAART to 50,000 people by March 2004.  The 
human costs of this procrastination are enormous.  It has been estimated that if the 
government opted to rollout HAART rapidly to reach 90% of all those who need it, 
then by 2015 average life expectancy would be 50 (as opposed to 42), there would be 
913,000 fewer maternal orphans than would be the case in the absence of a rollout 
(see Nattrass, 2004).  Similarly, if the government opted to boost the pace of its 
current rollout to this rapid rate, then there would be 2.3 million fewer AIDS cases in 
total between 2003 and 2015 and 430,000 fewer HIV infections1 (see Figure 2).   
 
 
 
Figure 1. HIV Prevalence in South Africa (% of population that is HIV-positive)  
                                                 
1 The ASSA model estimates that rolling out HAART helps prevent new HIV infections because 
people on HAART have lower viral loads and hence are less infectious during their lives – even though 
they live longer (for more discussion, see Nattrass (2004).  
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It is thus unsurprising that people working in the AIDS arena in South Africa are 
infused with a sense of frustration with government.  Those conducting research are 
under enormous pressure from AIDS activists and health practitioners to produce 
findings that could help promote the cause of a faster rollout.  This is the politically 
and emotionally charged context within which the two case studies presented below 
take place.  
 
 
 
 
Figure 2.  A Slow and Limited versus a Fast and Comprehensive HAART Roll-
out 
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Case One:   Repressing Social Science Research in the Supposed ‘Best-interests’ 
of the Patients and the NGO providing HAART 
 
In 2002, two employees of a large European non-government organisation (NGO) 
approached me to collaborate in a study of the socio-economic benefits of providing 
HAART in a resource-poor setting.  The NGO had, with the support of the Western 
Cape provincial government,2 been operating a pilot project to provide HAART in a 
local African township.  Their clinical data indicated that adherence was good, and 
that in terms of standard medical measures (viral loads, CD4 cell counts), almost all 
of their patients were responding positively to treatment.  The NGO thus decided to 
supplement these results with a socio-economic survey of the impact of providing 
HAART.   
 
They approached me for three reasons:  1) my background in AIDS and survey 
research; 2) the fact that the research unit I direct also operates an AIDS outreach 
programme in the local African townships; and 3) because they saw me as a natural 
ally because of the supportive work I had done for the Treatment Action Campaign’s 
court case to force the government to implement a mother to child transmission 
prevention programme (see chapter 4 of Nattrass, 2004).  In retrospect, this political 
dimension my selection as a ‘politically safe’ researcher should have been more 
carefully considered at the outset – but such is the benefit of hindsight.  
 
                                                 
2 Although the national Ministry of Health in South Africa has proved reluctant to rollout HAART, the 
Western Cape Provincial government has not been – and in fact has been proactive in securing the help 
of foreign charities and NGOs to help provide HAART to people who need it in the Western Cape.  
Most of the people on HAART in South Africa are located in the Western Cape as a result.  
430,000 extra HIV infections averted 
2,340,000 extra AIDS 
sick cases averted  
During our initial discussions, it became clear that their working hypothesis was that 
HAART would boost household income because previously sick people would 
become well enough to work (and because people who had left employment to 
become full-time caregivers would be able to return to work).  I warned them that this 
happy scenario might not materialise quite as they expected because of South Africa’s 
high unemployment rate.  Given that over a third of working-age adults in South 
Africa cannot find wage employment,3 there was no guarantee that better health 
would translate uniformly into better income.   
 
Undaunted, the employees of the NGO expressed their desire to embark on the study, 
and asked me to pilot it through the relevant medical research ethics committee at the 
University of Cape Town.4  This I did in my capacity as being listed as the University 
Principle Investigator (PI) on the application (with the senior employee of the NGO 
listed as the ‘Principal Investigator’ (PI)).  The NGO undertook to collect the data 
from their HAART patients.  I understood my role to be a purely academic one – i.e. 
to analyse the data and write papers for publication.  I signed no formal contract, but 
was happy with the wording that appeared on application to the Faculty of Health 
Sciences Research Committee.  In particular, under Section E – Financial and 
Contractual Information – the application recorded ‘no’ to the question: “Are there 
any restrictions or conditions attached to publication and/or presentation of the study 
results”.  I thus assumed that I would be free to present and publish any findings from 
the study.  
 
Although the NGO paid for the survey, I provided advice on the survey design and 
supplemented the project with additional resources from my research unit in the form 
of paying for data capture, facilitating the collection of extra comparative data, and 
supporting a Master’s student to work on the data.  This student, in turn, spent many 
hours at the NGO’s clinic conducting a quality control operation on the 
questionnaires.  It seemed to me, in other words, to be a genuine collaboration 
between medical practitioners/ researchers and social scientists.  
 
All went well until the Master’s student and I presented our first report to the NGO.  
The PI based at the NGO expressed her dissatisfaction with several results – the most 
important being that unemployment rates had risen in the sample of people on 
HAART.  I was not surprised by this result (indeed, I had tried to warn her to expect 
it) – but she clearly saw this as a negative reflection on the NGO’s intervention.  I 
tried to explain that the unemployment rate is calculated as the number of 
unemployed (i.e. people seeking work) divided by the labour force (i.e. the sum of the 
number of unemployed plus the number of employed).  People who are sick are non 
labour-force participants and do not get included in either the numerator or the 
denominator of the unemployment rate.  When people get better, they enter the labour 
force.  In a context of previously existing high unemployment, it is not surprising that 
these previously sick individuals would result in a rise in the unemployment rate.  
                                                 
3 According to the September 2003 Labour Force Survey, the official (strict) rate of unemployment 
(which includes only those without work who are also actively seeking it), was 28.2%.  If those who 
say they want work but are not looking for it are also included amongst the ranks of the measured 
unemployed (the broad definition), then the rate rises to 41.8%.   
4 All healthcare related research in South Africa has to have approval from a Research Ethics 
Committee registered with the National Health Research Ethics Council.  Many of these Research 
Ethics Committees are in tertiary institutions.  
Rather than celebrating the fact that people now felt well enough to seek work (even 
if most did not find it), the NGO PI wanted to suppress this result.  She assumed that 
because I was on the side of the AIDS activists in the political struggle to provide 
HAART, that I would automatically agree with her interpretation of what results we 
should present.  
 
In the course of this rather protracted confrontation over ‘the results’, it became clear 
to me that the NGO PI’s idea of ‘collaborating’ with me was for me to do the data 
analysis and initial writing, and then for her to select what should be included and 
what should be omitted/suppressed.  She did not provide us with written comments 
and never offered to write anything or contribute materially to the paper – but kept on 
insisting that I was the person who was ‘not collaborating’ because I was refusing to 
suppress or change the results.  
 
I then contacted the head of my university’s Senate Ethics Committee to ask him for 
his advice.  He initially interpreted the issue as being one of ‘authorship’ and referred 
me to the principles upheld by the International Committee of Medical Journal Editors 
– the key one being that ‘acquisition of funding, the collection of data, or general 
supervision of the research group, by themselves, do not justify authorship’.5  This 
suggests that the NGO PI had no basis for insisting on equal authorial status in 
deciding what did or did not go into the paper.  I also pointed out that the NGO PI had 
signed a statement saying that there were no “restrictions or conditions attached to 
publication and/or presentation of the study results” and asked him if this protected 
me from the harassment I was currently experiencing.  At this point, he observed that 
this particular clause was designed to protect university researchers from undue 
pressure from funders (such as pharmaceutical companies) who may have an interest 
in seeing one set of findings rather than another.  I asked whether I should be afforded 
the same protection from the NGO PI who clearly felt that her organisation had an 
interest in one set of findings rather than another.  He said that the case was 
complicated by the fact that the NGO PI was claiming to be a collaborator rather than 
merely a funder – and concluded that the available research ethics procedures were 
not designed to deal with problems arising between collaborators.    
 
Eventually, under pressure from one of my funders (who was expecting me to run a 
workshop on the research being undertaken by the Master’s student involved in the 
research), the student and I presented a couple of papers at an in-house workshop (to 
which a limited number of people were invited – including the NGO PI, but she 
declined).  Our papers included the results about labour market participation.  The 
NGO PI then wrote to me declaring the collaboration over, and demanding that if the 
Master’s student was to continue to gain access to ‘their’ data that she would need to 
get a new supervisor – who in turn was expected to sign an agreement saying that 
none of the data could be used in any publication.   
 
What are the lessons of this sorry saga?  To some extent, the problem was one of  
clashing personalities.  However, what struck me during the tiresome and draining 
process was that the NGO PI was convinced that she was acting in the best interests of 
the patients when she demanded that I perform massage and surgery on my papers.  
                                                 
5 “News from the International Committee of Medical Journal Editors” in Annals of Internal Medicine, 
vol.133, no.3: 229-31, 
She was worried that my findings may cause ‘bad press’ and in this way undermine 
the impact of this NGO-lead pilot project to provide HAART in a resource-poor 
setting.  She genuinely seemed to believe that I was pursuing narrow selfish academic 
goals, when I should be ‘collaborating with’, i.e. agreeing to abide by her 
interpretation of what results were politically strategic.  After all, as she pointed out 
on several occasions, she was ‘really’ helping people by being part of an NGO located 
in the middle of an African township whereas I operated out of a comfortable office 
on the slopes of Table Mountain.   
 
Her worry about possible negative publicity is understandable (although it should be 
said that nothing of the sort materialised once my papers entered the public domain – 
so in actual fact, her fears were unfounded).  But even if there had been the possibility 
of negative publicity, was this sufficient to justify suppressing the results?   I would 
bet that most social scientists would say no.  After all, it is precisely by exposing and 
analysing the complex ways that people respond to policy interventions and changes 
in their social environments that social scientists can alert us to new challenges.  
 
Let’s consider the controversial result once again.  The data showed that once people 
had their health restored by HAART, they entered the labour market – but that many 
of them did not find work.  In other words, a social scientist would conclude that if we 
care about the welfare of HAART patients, a broader range of services is necessary.  
Rather than simply worrying out their viral load (which is what medical researchers 
concentrate on) we should also be making sure that programs are put in place to help 
them find jobs.  By wanting to suppress the unemployment results, the NGO PI 
effectively put (what she believed to be) the interests of the NGO’s medical 
intervention first.  She may have believed that this was in the interests of the patient 
(on the grounds that good publicity is good for the NGO which is good for the 
patients), but this conception of the interests of the patient was a very narrow one.  It 
discounted entirely the important role that social science research might play in 
guiding the design of other HAART provision programs in other sites.   
 
But was the issue merely that she believed (doctor-like) that medical research is 
morally and intellectually superior to social science research and that her views thus 
ought to prevail because she had the best interests of the patients at heart?  Again, I 
think not. There is another, broader, structural issue at heart.  When medical 
researchers are also medical practitioners, there is a real danger that their intellectual 
judgement (and output) may be clouded.  After all, if you are putting your heart and 
soul into working to help people, and then the research shows that they are not being 
helped in the ways that you had hoped – you may be under particular emotional 
pressure to massage the presentation of the findings.   For this reason, particular 
attention needs to be paid to the conduct of the researchers collaborating under such 
circumstances.  There is probably a case for developing codes of conduct to help 
manage the kind of conflict we found ourselves immersed in.  
 
 
Case Two: Gate-keeping by Medical Practitioners/Researchers 
 
In addition to several large NGO’s providing HAART, the wider Cape Town 
Metropolitan area is also home to a couple of treatment and vaccine interventions 
funded by pharmaceutical companies.  All of these entail collaboration with the 
Western Cape government (which provides the clinics) and most have strong links 
with university-based medical researchers – some of whom also offer medical or 
related support services to the projects.  
 
In this world of over-lap between service provision and research interests, patients are 
simultaneously beneficiaries and research subjects.  They enter a world entirely 
controlled by doctor/researchers.  Although the clinics are technically under the 
control of the government, decision-making power in effect is ceded to the largely 
foreign-funded doctors and researchers who run the intervention.   They decide who 
can be on the premises, what research is ‘acceptable’, and who can interview the 
patients.  This gatekeeper role has serious implications for social scientists trying to 
conduct research – as one of the PhD students funded through my research unit 
discovered to her cost.   
 
The student, a clinical psychologist, wanted to conduct research into the 
psychological well-being and coping of low socio-economic status mothers in the era 
of HAART.  Her research entailed recruiting 75 HIV-positive mothers and 
interviewing them when they start HAART, and then again after four, 12 and 24 
weeks on treatment.6  A sample of 75 HIV-negative mothers from the community was 
to be recruited as the comparison group.  The aim of the research was to explore the 
challenges to women’s care-giving and psychological well-being posed by negotiating 
the multiple roles of living with HIV, caring for young children and dealing with the 
general stressors associated with poverty.  She was particularly interested in drawing 
out the implications of these multiple roles for women’s adherence to HAART.  
 
In addition to interviewing the women, the student stated her intention to ask the 
participants for permission to access their medical files so that she could collect data 
on CD4 counts, viral loads, clinical staging and adherence information.   She stressed 
that this information would only be collected at the convenience of the clinic.  In her 
research protocol, she acknowledged that she would need the help of clinic staff in 
accessing the files, but argued that this cost was small in relation to the benefits of her 
study.  In particular, she pointed out that she and her researchers are clinically trained 
(and registered with the Health Professions and Social Work Councils) and thus in a 
position to provide useful feed-back to the clinic on patients who were deemed to be 
at risk for poor adherence due to their mental health and social difficulties.  She also 
pointed out that some of the empirical indicators being developed in her study may 
become useful tools for the counselors associated with the HAART program to use in 
the future should they wish to asses the extent to which a patient’s psychological well-
being places them at risk for poor adherence:  “ More broadly, the research aims to 
make recommendations about the kinds of psychosocial services which can enhance 
women patients’ quality of life and psychological well-being, as well as enhancing 
their adherence to treatment”.7 
 
The student developed her research protocol through consultation with her supervisors 
in the Psychology Department, and those who were funding her study.  She then 
                                                 
6 The questionnaires were designed to take an hour.  They covered socio-demographic and household 
information, care-giving history and HIV and other health-related information as well as four brief 
standardised measures to assess depression, anxiety, social support and coping strategies.  
 
7 Student research protocol presented to the University and to the various clinics.  
approached a clinic in a local African township for permission to invite potential 
respondents to participate in her study.  The medical practitioners/researchers 
associated with the HAART project at the clinic considered her request to approach 
some of their patients for study purposes – but rejected it.  As can be seen from the 
three reasons listed below, the fact that the research and HAART intervention was 
funded in part through a large pharmaceutical company seemed to pose particular 
problems.  The reply she got gave her the following reasons for denying her access to 
patients:  
 
1) “the population is over-researched and your study is not the primary focus of 
the research”  (‘the research’ referring, of course, to the research already being 
conducted by the medical professionals at the clinic); 
2) “None of the (pharmaceutical company) Exco members are senior authors of 
the project.” (‘the project’ referring of course to the student’s doctoral 
project); and 
3)  “It has not been approved by the same Ethics Committee as the other 
(pharmaceutical company) projects” 
 
The student was referred to a clinic in a second African township – but was again 
turned down by the relevant committee of medical practitioner/researchers.  This time 
she was turned down on the following grounds: 
 
1) They were concerned about the “space implications” (i.e. her finding a space 
somewhere in the clinic to do the interviews);  
2) They did not believe that there were “sufficient direct and tangible benefits to 
the clinic patients” who would participate in the study;  
3) They were concerned about the “amount of time” which respondents would 
have to spend on the study; and 
4) They did not “feel that the research addresses the needs which they have as a 
clinic at this point in time, and only want to permit research which does so”. 
 
The student responded to the main research gatekeeper of this clinic by saying that the 
demands on the clinic posed by her study were minimal.  The clinic was to be used 
only as the initial point of contact in the form of a five-minute presentation to 
potential participants at the end of a counselling session inviting them to become 
respondents in her study.  After than, no further demands were going to be made on 
the clinic – other than a monthly visit to check on clinical indicators such as CD4 cell 
counts (for those patients who have given permission for such access to their medical 
information).   
 
The student also reiterated that her research could be of potential direct and 
immediate benefit to the counsellors who work with people on antiretroviral treatment 
as well as to the patients themselves:   
“In addition, on the positive side, we could provide support (either formally or 
informally, depending on their needs) to the counseling team and thereby in that 
way contribute to the very important role which they play in ensuring that the 
patient's well-being does not place them at risk for poor adherence thereby 
undermining desired viral load suppression.  Depending on the clinic's need, 
feedback from the research could either be restricted to liaising with the 
counseling team, or direct input could also be given to the other members of the 
clinic team if relevant and useful.  Whichever approach minimizes the negative 
impact of our presence on the running of the service, while maximizing the 
support and benefits, is desirable for me.” 
 
She never got a reply to this email.   
 
What are the lessons of this case study?  I think there are three: 
1) When medical researchers exercise control over very large health 
interventions, they are in a position to prioritise their own (narrowly defined) 
research interests over that of other researchers.  Simply because they are 
delivering a medical service, they effectively have control over a facility (like 
a clinic) – even though this may in fact be the ultimate preserve of the 
government.   
2) True to the medical paradigm of benefit and risk, medical researchers seem to 
believe that only their research is of direct benefit to their patients.  They 
certainly appeared not to accept the argument that psychological research 
could help patients directly (through referrals of the kind suggested by the 
doctoral student) and indirectly by helping to guide policy and practice with 
regard to support groups.   
3) Medical practitioner/researchers are accountable to no-one when they deny 
other researchers access to ‘their’ patients.  Their effective control over clinics 
is not a subject for ethical review, and hence it is impossible to hold them to 
account for their seemingly capricious and self-interested actions.   
 
When medical researcher/practitioners effectively control the provision of health 
services, they have enormous de facto power to assert their own research interests 
over those of social scientists.  It is they who decide who has access to ‘their’ patients 
(or data pertaining to ‘their’ patients) – and what is and what is not in the interests of 
their patients.   
 
This, I believer, runs counter to the spirit of the principle of informed consent.  
Although the principle of informed consent was designed to ensure that prospective 
research subjects have the right to refuse to participate – it surely also protects these 
same subjects from others deciding on their behalf that it is not in their best interests 
to participate.  The principle should surely be that research subjects have the right to 
decide whether they want – or do not want – to participate.  In my experience (and 
others – see e.g. Pahl, 2005), research subjects often enjoy being interviewed and 
having the opportunity to discuss matters of concern to them.  Other research subjects, 
of course, could get irritated by the research process – but they can always refuse to 
participate at any point (as is typically – if not always – pointed out in consent forms).  
Most often, the ‘risks’ to the social science research subject tend to be little more than 
the opportunity cost of the time taken to conduct the interview.  In most cases, it is the 
research subject who is in the best position to calculate the risks and benefits of 
participating in the research.  Medical practitioner/researchers are often not in an 
appropriately informed position to make the judgment call.   
 
Most research ethics codes are silent on the issue of ensuring that potential research 
subjects have the right to choose whether they do or do not want to participate in 
research.  The European Group on Ethics in Science and New Technologies (EGE, 
2003) and the Nuffield Council on Bioethics (UK) (NCOB, 2002) note that in some 
local contexts, it may be appropriate to obtain family- or community-level agreement 
before approaching research subjects (see discussion in NCOB, 2005: 73).  However, 
this is a concession to local culture – it cannot be used to justify giving medical 
practitioner/researchers the right to make decisions on the behalf of their patients – 
especially in cases where these same medical practitioner/researchers are not 
disinterested observers.     
 
 
Conclusion 
 
In conclusion I would like to reiterate that the two case studies presented here 
subjective experiences, do not represent any official position and would obviously 
benefit from the addition of the medical practitioner/researcher’s other side of the 
story.  It was written in the spirit of generating debate about some of the lesser-
considered ethical issues that arise when social scientists and medical 
practitioner/researchers collide in the field.  It is also worth reiterating that the cases I 
discussed occurred in a particularly charged environment in which research has 
political and policy implications.   
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